RxDoctor Payments Data

Katherine Kaufman, MD

Rheumatology · Pollocksville, NCNPI 1982963245

Payments from drug & device makers

$2,572in general payments, 2019–2025

Across 137 payments — averaging $18.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • AbbVie$378
  • Lilly USA, LLC$217
  • Aurinia Pharma U.S., Inc.$183
  • GSK$167
  • Sanofi$148
  • plus $352 from 10 others

What the payments were for

  • Food & beverage$2,560100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,572 in reported general payments places this provider in the 40th percentile of 210 rheumatology providers in North Carolina.

See all rheumatology providers in North Carolina

Medicare billing

Part B allowed, 2024
$602,295
Medicare patients
263
Services billed
32,467

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab166$1,394,456
Enbrel SureclickEtanercept126$992,354
Orencia ClickjectAbatacept21$162,750
RinvoqUpadacitinib24$153,181
Cosentyx Sensoready PenSecukinumab16$128,864
Cosentyx Unoready PenSecukinumab12$102,521
Hydroxychloroquine Sulfate432$16,149
MethotrexateMethotrexate Sodium350$5,367
Celecoxib121$3,182
Colchicine34$2,600
Prednisone270$1,685
Mycophenolate Mofetil24$1,544
Pilocarpine Hcl23$1,541
Gabapentin69$1,382
Leflunomide33$1,180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$378$153,18124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 210 rheumatology providers in North Carolina.

Other rheumatology in Pollocksville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →